Los Angeles Hematology-Onclgy is categorized under Medical Centers in Glendale, CA .
Los Angeles Hematology-Onclgy was established in 0, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Medical Centers business, which does work in the B2C market, and is classified as a Medical Centers, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Lasika Seneviratne at the company’s single location by writing to 222 West Eulalia St # 100c, Glendale, California CA 91204 or by phoning (818) 553-8160. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Los Angeles Hematology-Onclgy |
| Contact Person: | Lasika Seneviratne |
| Address: | 222 West Eulalia St # 100c, Glendale, California 91204 |
| Phone Number: | (818) 553-8160 |
| Website Address: | lacancer.net |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Medical Centers |
| SIC Code: | 8011 |
| NAICS Code: | 6211110 |
| Share This Business: |
Los Angeles Hematology-Onclgy was started in 0 to provide professional Medical Centers under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Lasika Seneviratne for inquiries that concern Los Angeles Hematology-Onclgy by calling the company number (818) 553-8160, as your correspondence is most welcome. Additionally, the physical location of the single location of Los Angeles Hematology-Onclgy can be found at the coordinates 34.12659,-118.25675 as well as the street address 222 West Eulalia St # 100c in Glendale, California 91204.
For its online presence, you may visit Los Angeles Hematology-Onclgy’s website at lacancer.net and engage with its social media outlets through on Twitter and on Facebook.